Skip to content

A single-center randomized controlled trial for autologous platelet rich plasma used in endometrial repair after hysterscopic adhesiolysis

A single-center randomized controlled trial for autologous platelet rich plasma used in endometrial repair after hysterscopic adhesiolysis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000031151
Enrollment
Unknown
Registered
2020-03-23
Start date
2020-04-01
Completion date
Unknown
Last updated
2020-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

intrauterine adhension

Interventions

Control Group:estrogen therapy

Sponsors

The Affiliated Yantai Yuhangding Hospital of Qingdao University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: (1) Women of childbearing aged 18 to 40 years old undergoing hysterscopic adhesiolysis; (2) Patients with moderate and severe uterine adhesion; (3) With regular menstruation and ovulation; (4) Agree to participate in the clinical study and sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) Previous surgery history for intrauterine adhesion; (2) Thrombosis, cardiovascular disease and respiratory disease or previous history; (3) Serious uterine malformation, endometrial tuberculosis or polyp, large intramural myoma, genital malformation and serious adenomyosis; (4) Acute reproductive tract infection; (5) Severe hepatorenal insufficiency: ALT>80U/L,Cr>100µmol/L; (6) There are history of thrombosis or high risk factors of thrombosis, such as antiphospholipid syndrome; (7) Patients with diseases that are not suitable to be treated with high dose estrogen; (8) Abnormal karyotype; (9) Abnormal thyroid or adrenal function; (10) History of pelvic tumor or other malignant tumor or received pelvic radiotherapy; (11) The use of drugs (such as hormones, prostaglandin inhibitors, psychotropic drugs) that may interfere with the evaluation of the study; (12) Patients with poor compliance such as inability or unwillingness to contact after discharge; (13) They had taken other experimental drugs or were participating in other clinical studies within one month before inclusion; (14) The doctor in charge thinks it is not suitable to participate in the clinical study.

Design outcomes

Primary

MeasureTime frame
thickness of endometrium around ovulational peried;AFS;the clinical pregnancy rate;

Secondary

MeasureTime frame
menstrual quantity;the pregnancy rate;abortion rate;

Countries

China

Contacts

Public ContactHongchu Bao

The Affiliated Yantai Yuhangding Hospital of Qingdao University

hongchubao@outlook.com+86 15653561760

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026